BioSpace News Archive

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan Healthcare Conference at 2:15 p.m. PT (5:15 p.m. ET) on Monday, January 8, 2024 in San Francisco, CA.

Ultragenyx Pharmaceutical Inc. reported the grant of 30,325 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced today that it has completed the acquisition of Propella Therapeutics, Inc. (President and CEO: William Moore, “Propella”), and has become a wholly owned subsidiary of Astellas as of U.S. Eastern Time December 21, 2023.

AstraZeneca and Ionis’ WAINUA™ (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.

Polaris Group announced that its board approved to increase the acquisition of Genovior Biotech’s shares to 100%.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024.

Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announced the closing of its previously announced private placement with a gross proceed of $5.3 million.

R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2023, at 10:30am ET.

MediciNova, Inc. today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah.

Ono Pharmaceutical Co., Ltd. announced that it has entered into a discovery collaboration agreement with EVQLV, INC, to generate novel antibodies against multiple targets selected by Ono, for the development of innovative antibody drugs.